The surface molecule signature of primary human acute myeloid leukemia (AML) cells is highly associated with NPM1 mutation status Leukemia (2012) 26, 557-559; doi:10.1038/leu.2011 published online 9 September 2011 Even though human acute myeloid leukemia (AML) is characterized by an expansion of malignant myeloblasts, these immature leukemic cells can show signs of differentiation both by morphological examination and by flow-cytometric analysis of membrane molecules.
The surface molecule signature of primary human acute myeloid leukemia (AML) cells is highly associated with NPM1 mutation status Even though human acute myeloid leukemia (AML) is characterized by an expansion of malignant myeloblasts, these immature leukemic cells can show signs of differentiation both by morphological examination and by flow-cytometric analysis of membrane molecules. 1 Analysis of this molecular profile is mainly used as a diagnostic tool to detect panmyeloid or lineage-associated differentiation markers, and thereby distinguish between myeloblasts and lymphoid blasts. 2 On the other hand, cytogenetic and molecular genetic analyses are mainly used for prognostic classification of patients. The most important mutations are then FLT3-ITD, which has an adverse prognostic impact, and NPM-1 mutations, which can be associated with a favorable prognosis. 2 Certain cytogenetic and molecular genetic abnormalities are associated with signs of AML cell differentiation, including NPM-1 mutations, which are associated with monocytic morphology and low expression of the CD34 stem cell marker. 3 These last observations suggest that the cell of origin of the NPM-1 mutation is a myeloid progenitor and not the most immature stem cells. In this context we have therefore investigated in more detail the associations between NPM-1 mutations and AML cell differentiation as defined by a limited number of well-characterized surface membrane molecules.
The membrane molecule profile was investigated by flow cytometry for 184 consecutive AML patients. All patients were examined with regard to the expression of CD11c (expressed on monocytes), CD13 (monocytes, neutrophils), CD14 (mainly expressed on monocytes, at lower levels on neutrophils), CD15 (mainly neutrophils, also monocytes), CD33 (appears on myelomonocytic precursors after CD34), CD34 (immature hematopoietic cells), CD45 (leukocytes) and HLA-DR. 4 The French-American-British (FAB) classification was used for morphological evaluation of the differentiation status, 5 and analysis for FLT3 and NPM-1 mutations was performed as previously described. 6 Bioinformatical analyses were performed using the J-Express 2009 analysis suite (MolMine AS, Bergen, Norway) 7 and hierarchical clustering was performed with Pearson's correlation as distance measure and complete weighted linkage. Based on the surface expression level of this limited number of differentiation markers, the patients could be classified by hierarchical clustering into distinct subsets (Figure 1 ). The patients were classified into two major clusters, the most important difference between these two subsets being a low CD34 expression in Cluster I and a high expression in Cluster II.
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The heterogeneity within each of these two patient subsets was limited ( Figure 2 ).
Cluster I patients could be further subdivided into two different subsets ( Figure 1 ): Cluster Ia was characterized by the phenotype CD34 low HLA-DR low , whereas Cluster Ib patients showed the phenotype CD34 low HLA-DR high and a high frequency of patients with morphological signs of monocytic differentiation (FAB AML-M4/M5). The lack of HLA-CR suggests a more mature phenotype of patients in this subset. 4 Cluster II patients could also be divided into two subsets: patients in the IIa cluster showed the phenotype CD34 high CD33 high , whereas patients in Cluster IIb showed the more immature phenotype, CD34 high CD33 low . FLT3 mutations were observed at similar frequencies in all the four subsets. In contrast, NPM-1 mutations showed a significantly increased frequency in Cluster I compared with Cluster II (51.5% versus 4.8%, Po0.0001, w 2 -test) and were not detected for any patient in the immature Cluster IIb. Finally, the frequencies of patients with both FLT3-ITD and NPM-1 mutations did not differ between the four subsets.
In our present study we included a large number of consecutive/unselected AML patients and the patient clusters were defined on the basis of membrane molecule analyses for all patients. A majority of these patients were investigated for FLT3 and NPM-1 mutations, and these analyzed patients also represent a consecutive or unselected subset of the whole group. Thus, even though mutational data were not available for all patients, the absence of patient selection allows a reliable analysis of mutational frequencies for the various patient subsets.
Previous studies have shown that NPM-1 mutations are associated with FAB-M4/M5 morphology and low or absent CD34 expression. 3 Our present results show that NPM-1 mutations were seen especially in CD34-negative patients, and with no difference between CD34-negative patients with or without morphological signs of monocytic differentiation. Furthermore, a very striking observation was the absence of NPM-1 mutations among CD34 þ CD33 À patients, the patient subset showing the most immature surface marker phenotype. þ and CD34 À populations. The figure displays the pairwise correlation between the 184 patient samples based on the AML cell expression of cell surface differentiation markers. Red and green colors indicate a high positive or negative correlation between samples, respectively. Based on this identification CD34 expression was identified as the main discriminative marker, and the patients could then be divided into CD34 high and CD34 low subsets. Each subset showed a limited heterogeneity when comparing patients within the same subset, indicated by red color in the upper left and lower right squares, whereas there was a considerable difference between the two subsets, as indicated by the green color in the lower right and upper left squares.
On the basis of our present study, we conclude that the most striking observation is not the previously described positive association between monocytic differentiation and NPM-1 mutations or the negative association between these mutations and CD34 expression, 3, 8 but rather the absence of NPM-1 mutations among patients with the most immature CD33 À CD34 þ AML cell phenotype. Thus, NPM-1 mutations are associated with myeloid differentiation, an observation consistent with the hypothesis that the cell of origin of the NPM-1 mutation is a common myeloid progenitor. 8 
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The authors declare no conflict of interest. Follicular lymphoma (FL) is characterized by the balanced chromosomal translocation t(14;18)(q32;q21) in about 80-90% of the cases. This primary event is not sufficient for emergence of FL, and acquisition of secondary genetic alterations is necessary to full disease manifestation. Genome-wide studies revealed recurring sites of copy number alterations and acquired uniparental disomies (aUPD).
1-3 1p36 region alterations (deletions and aUPD) were described as one of the most frequent secondary genetic abnormality in FL, 1 and del(1)(p36) was considered as a significant predictor of poor overall survival. 2 In an initial prospective study based on 20 de novo and untreated FL, we performed a genome-wide approach using comparative genomic hybridization (CGH) and single-nucleotide polymorphism array technologies on cell-sorted tumor and microenvironment compartments to evaluate genetic changes involved in FL. We found that 25% of the cases presented a deletion of the region 1p36.32 and 40% of the cases presented an aUPD 1p36. Thus, 1p36.32 alterations were the most frequent additional genetic abnormality (67%) in our cohort, and our analysis delineated a minimum deleted region of B12 kb in band 1p36.32 comprising a unique candidate gene, TNFRSF14. This latter is a member of the tumor necrosis factor receptor (TNFR) superfamily and its stimulation in lymphoma cells via LIGHT ligand enhances Fas-induced apoptosis and could improve tumor immunogenicity. 4 Additionally, TNFRSF14 activation by LIGHT inhibits proliferation of adenocarcinoma cells, 5 both observations suggesting that TNFRSF14 signaling might have a tumor suppressor role.
To further investigate this gene, we designed a dedicated QMPSF (quantitative multiplex PCR of short fluorescent fragments) assay, targeting the eight exons of TNFRSF14 (Supplementary Table S1 ) to evaluate the deletion status of the gene in a larger cohort comprising 30 cell-sorted (FL1 to FL30, 20 of these cases were used for our initial study) and 51 additional non-sorted de novo FL (FL31 to FL81). Twenty patients presented a complete heterozygous deletion of TNFRSF14 and one patient presented a partial heterozygous deletion. Three patients had a complete (FL16) or partial (FL8, FL18) homozygous deletion. Array-CGH analyses showed that FL16 presented a large deletion 1p36.11-p36.33, comprising a homozygous deletion from PLCH2 to MMEL1, which are located in telomeric and centromeric position, respectively, with regard to TNFRSF14; FL8, with a homozygous deletion from exons 4 to 8, showed an isolated bi-allelic deletion of TNFRSF14 (array-CGH probe being located in exon 8; Supplementary Figure S1A) , and FL18 homozygously deleted from exons 5 to 8 had a bi-allelic deletion in 1p36.32 associated with telomeric breakpoint in TNFRSF14 (Supplementary Figure  S1B) . QMPSF results were consistent with array-CGH data. Altogether, partial or complete deletion of TNFRSF14 was found in 30% of the FL (24 cases); the remaining 57 patients had two non-deleted copies of the TNFRSF14 gene.
As somatic mutations were commonly associated with tumorigenesis 6 and copy-neutral loss of heterozygosity in
